I’m sorry but I’ll have to disagree here. The clinical trial update in Q10 should also contain forward looking statements (there are many in them). If you have informed the markets about delays before but you have plans (or are currently) continuing, you should inform the market. If you did not do that then there was no plan to progress or you did not inform the market properly. So, I take it there was no plan (because of no sufficient funds) to restart GvhD. NP statements contradict the Q10.